Biotech News
Related news
OCSOculis2026-10-22 06:00 EST
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
OCSOculis2026-08-24 08:00 EST
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
KPRXKiora Pharmaceuticals2026-10-29 11:00 EST
Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan
RHHBYRoche Holdings AG2026-10-21 12:00 EST
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
OCGNOcugen2026-10-06 11:02 EST
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
OKYOOKYO Pharma2026-10-06 11:00 EST
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
OKYOOKYO Pharma2026-07-20 11:00 EST
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
PRQRProQR Therapeutics2026-06-25 10:25 EST
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
EYPTEyePoint Pharmaceuticals2026-07-30 11:00 EST
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
PRQRProQR Therapeutics2026-09-09 12:00 EST
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-11-03 21:05 EST
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
OCSOculis2026-11-02 07:00 EST
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
OCSOculis2026-10-29 09:39 EST
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
OCSOculis2026-10-22 06:00 EST
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
OCSOculis2026-10-20 06:00 EST
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Stock data
- Close
- 6.83 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States